Next Article in Journal
The Use of Orientation Templates and Free-Hand Implant Insertion in Artificial Mandibles—An Experimental Laboratory Examination in Fifth-Year Dental Students
Previous Article in Journal
Wind Instrumentalists and Temporomandibular Disorder: From Diagnosis to Treatment
Previous Article in Special Issue
Meth Mouth—A Growing Epidemic in Dentistry?
Article Menu

Export Article

Open AccessComment
Dent. J. 2018, 6(3), 42; https://doi.org/10.3390/dj6030042

Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

1
Oncology Unit, Azienda Ospedaliera di Alessandria, 15121 Alessandria, Italy
2
Oral Medicine Unit, Università di Palermo, 90127 Palermo, Italy
3
Service D’épidémiologie et de Santé Publique, Hôpitaux Universitaires Paris-Sud, 94270 Paris, France
4
Haematology Unit, Azienda Ospedaliera di Alessandria, 15121 Alessandria, Italy
5
Regional Center for Prevention, Diagnosis and Treatment of Medication and Radiation-Related Bone Diseases of the Head and Neck, University of Padua, 35136 Padua, Italy
*
Author to whom correspondence should be addressed.
Received: 22 July 2018 / Revised: 22 August 2018 / Accepted: 27 August 2018 / Published: 1 September 2018
Full-Text   |   PDF [197 KB, uploaded 17 September 2018]

Abstract

The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid. View Full-Text
Keywords: osteonecrosis of the jaw; ONJ; osteonecrosis; jaw; medication-related osteonecrosis of the jaw; MRONJ; multiple myeloma; denosumab; zoledronic acid osteonecrosis of the jaw; ONJ; osteonecrosis; jaw; medication-related osteonecrosis of the jaw; MRONJ; multiple myeloma; denosumab; zoledronic acid
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Fusco, V.; Campisi, G.; de Boissieu, P.; Monaco, F.; Baraldi, A.; Numico, G.; Bedogni, A. Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology. Dent. J. 2018, 6, 42.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Dent. J. EISSN 2304-6767 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top